Akebia Therapeutics (AKBA) to Release Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $48.3730 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Akebia Therapeutics Stock Down 1.3%

Shares of Akebia Therapeutics stock traded down $0.02 during midday trading on Friday, reaching $1.17. 941,067 shares of the company’s stock traded hands, compared to its average volume of 3,341,941. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.80 and a current ratio of 1.94. Akebia Therapeutics has a 52 week low of $1.14 and a 52 week high of $4.08. The company’s 50 day simple moving average is $1.47 and its 200 day simple moving average is $2.20. The company has a market cap of $309.16 million, a price-to-earnings ratio of -16.64 and a beta of 0.38.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Piper Sandler cut their target price on Akebia Therapeutics from $6.00 to $4.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. BTIG Research reissued a “buy” rating and set a $5.00 price objective on shares of Akebia Therapeutics in a report on Tuesday, December 2nd. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Akebia Therapeutics in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akebia Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $5.60.

Insider Buying and Selling

In related news, CAO Richard C. Malabre sold 49,524 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.39, for a total transaction of $68,838.36. Following the completion of the transaction, the chief accounting officer directly owned 299,390 shares in the company, valued at $416,152.10. This represents a 14.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AKBA. Cibc World Markets Corp acquired a new stake in Akebia Therapeutics during the fourth quarter worth about $27,000. Caption Management LLC bought a new stake in shares of Akebia Therapeutics in the 4th quarter worth approximately $40,000. Baird Financial Group Inc. lifted its position in shares of Akebia Therapeutics by 23.0% in the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 4,000 shares during the period. Polymer Capital Management US LLC grew its holdings in shares of Akebia Therapeutics by 49.5% during the 3rd quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 6,034 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Akebia Therapeutics during the second quarter valued at approximately $62,000. Institutional investors and hedge funds own 33.92% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.